Saturday, October 3, 2026

EUR/JPY Bearish By 3% In The Last 21 Sessions

ViaNews Editorial Team

December 25, 2023

EUR/JPY Bearish By 3% In The Last 21 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 3.66% for the last 21 sessions. At 22:11 EST on Sunday, 24 December, EUR/JPY (EURJPY) is $156.77.

EUR/JPY's yearly highs and lows, it's 14.093% up from its 52-week low and 4.571% down from its 52-week high.

News about

  • According to FXStreet on Friday, 22 December, "Moreover, oscillators on the daily chart are holding deep in the negative territory, suggesting that the path of least resistance for the USD/JPY pair is to the downside. ", "This, in turn, warrants some caution before placing aggressive bullish bets around the USD/JPY pair as traders now look to the US Core Personal Consumption Expenditure (PCE) Price Index for a fresh impetus. "
  • Usd/jpy forecast: struggle against yen - 22 December 2023. According to DailyForex on Friday, 22 December, "The USD/JPY experienced a significant drop during Thursday's trading session, primarily driven by the continuous decline in interest rates within the United States. "
  • Usd/jpy rebounds into new Friday high, aimed for 143.00. According to FXStreet on Friday, 22 December, "The USD/JPY set a new high for Friday at 142.66, stopping just short of the 50-hour Simple Moving Average (SMA) as the pair gets hung up on near-term resistance levels.", "The pair remains constrained at the 200-day SMA rising into the 143.00 handle, and the USD/JPY is down over six percent from November's peak bids near 151.90."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com